Skip to main content
Top
Published in: Clinical Rheumatology 5/2012

01-05-2012 | Original Article

Correlation of serum CX3CL1 level with disease activity in adult-onset Still's disease and significant involvement in hemophagocytic syndrome

Authors: Tsuyoshi Kasama, Hidekazu Furuya, Ryo Yanai, Kumiko Ohtsuka, Ryo Takahashi, Nobuyuki Yajima, Yusuke Miwa, Kazuo Kobayashi

Published in: Clinical Rheumatology | Issue 5/2012

Login to get access

Abstract

To investigate the characteristics of patients with adult-onset Still's disease (AOSD), serum cytokines and chemokines were measured to examine their associations with systemic manifestations of AOSD, especially hemophagocytic syndrome (HPS). Nineteen patients diagnosed with AOSD were enrolled. Serial serum samples were obtained from patients with AOSD in both active and inactive stages and controls. The concentrations of cytokines and chemokines, including IL-18, soluble IL-2 receptor (sIL-2R), CX3CL1, CXCL8, CXCL10, CCL2, and CCL3, were determined using enzyme-linked immunosorbent assay. Multivariate analysis was used to evaluate the correlations among serum chemokine levels, disease activity, and the clinical features of AOSD. Significantly higher serum levels of all cytokines and chemokines were observed in patients with active, untreated AOSD than in controls. The level of CX3CL1, but not other chemokines, was elevated in AOSD patients and was positively correlated with clinical activity and the levels of CRP, ferritin, IL-18, and sIL-2R. Among the 19 patients with AOSD, four patients also had HPS. Serum CX3CL1 and ferritin were significantly higher in AOSD patients with HPS than in those without HPS. The serum CX3CL1 level may be used as a clinical marker to assess the disease activity of AOSD, and high serum CX3CL1 and ferritin in patients with AOSD reflected the presence of HPS. The association between the chemokine profile and distinct clinical manifestations or various patterns of disease progression indicates that the pathogenesis of AOSD is heterogeneous.
Literature
1.
go back to reference Pouchot J, Sampalis JS, Beaudet F, Carette S, Decary F, Salusinsky-Sternbach M et al (1991) Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine 70:118–136PubMedCrossRef Pouchot J, Sampalis JS, Beaudet F, Carette S, Decary F, Salusinsky-Sternbach M et al (1991) Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine 70:118–136PubMedCrossRef
2.
go back to reference Efthimiou P, Kontzias A, Ward CM, Ogden NS (2007) Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy? Nat Clin Pract Rheumatol 3:328–335PubMedCrossRef Efthimiou P, Kontzias A, Ward CM, Ogden NS (2007) Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy? Nat Clin Pract Rheumatol 3:328–335PubMedCrossRef
3.
go back to reference Schwarz-Eywill M, Heilig B, Bauer H, Breitbart A, Pezzutto A (1992) Evaluation of serum ferritin as a marker for adult Still's disease activity. Ann Rheum Dis 51:683–685PubMedCrossRef Schwarz-Eywill M, Heilig B, Bauer H, Breitbart A, Pezzutto A (1992) Evaluation of serum ferritin as a marker for adult Still's disease activity. Ann Rheum Dis 51:683–685PubMedCrossRef
4.
go back to reference Sharma M (2010) Chemokines and their receptors: orchestrating a fine balance between health and disease. Crit Rev Biotechnol 30:1–22PubMedCrossRef Sharma M (2010) Chemokines and their receptors: orchestrating a fine balance between health and disease. Crit Rev Biotechnol 30:1–22PubMedCrossRef
5.
go back to reference Scheinberg MA, Chapira E, Fernandes ML, Hubscher O (1996) Interleukin 6: a possible marker of disease activity in adult onset Still's disease. Clin Exp Rheumatol 14:653–655PubMed Scheinberg MA, Chapira E, Fernandes ML, Hubscher O (1996) Interleukin 6: a possible marker of disease activity in adult onset Still's disease. Clin Exp Rheumatol 14:653–655PubMed
6.
go back to reference Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M et al (2001) Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 44:550–560PubMedCrossRef Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M et al (2001) Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 44:550–560PubMedCrossRef
7.
go back to reference Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS et al (2003) Serum cytokine profiles in patients with adult onset Still's disease. J Rheumatol 30:2422–2427PubMed Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS et al (2003) Serum cytokine profiles in patients with adult onset Still's disease. J Rheumatol 30:2422–2427PubMed
8.
go back to reference Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S et al (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48:124–131PubMedCrossRef Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S et al (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48:124–131PubMedCrossRef
9.
go back to reference Grom AA (2003) Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities? Curr Opin Rheumatol 15:587–590PubMedCrossRef Grom AA (2003) Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities? Curr Opin Rheumatol 15:587–590PubMedCrossRef
10.
go back to reference Larroche C, Mouthon L (2004) Pathogenesis of hemophagocytic syndrome (HPS). Autoimmun Rev 3:69–75PubMedCrossRef Larroche C, Mouthon L (2004) Pathogenesis of hemophagocytic syndrome (HPS). Autoimmun Rev 3:69–75PubMedCrossRef
11.
go back to reference Wong KF, Hui PK, Chan JLC (1991) The acute lupus hemophagocytic syndrome. Ann Int Med 114:387–390PubMed Wong KF, Hui PK, Chan JLC (1991) The acute lupus hemophagocytic syndrome. Ann Int Med 114:387–390PubMed
12.
go back to reference Onishi R, Namiuchi (1994) Hemophagocytic syndrome in a patient with rheumatoid arthritis. Intern Med 33:607–611PubMedCrossRef Onishi R, Namiuchi (1994) Hemophagocytic syndrome in a patient with rheumatoid arthritis. Intern Med 33:607–611PubMedCrossRef
13.
go back to reference Negishi M, Kasama T, Iwabuchi H, Kanemitsu H, Ide H (2002) Autoimmune-associated hemophagocytic syndrome in a patient with rheumatoid arthritis. Clin Rheumatol 21:87–88PubMedCrossRef Negishi M, Kasama T, Iwabuchi H, Kanemitsu H, Ide H (2002) Autoimmune-associated hemophagocytic syndrome in a patient with rheumatoid arthritis. Clin Rheumatol 21:87–88PubMedCrossRef
14.
go back to reference Yajima N, Wakabayashi K, Odai T, Isozaki T, Matsunawa M, Miwa Y et al (2008) Clinical features of hemophagocytic syndrome in patients with dermatomyositis. J Rheumatol 35:1838–1841PubMed Yajima N, Wakabayashi K, Odai T, Isozaki T, Matsunawa M, Miwa Y et al (2008) Clinical features of hemophagocytic syndrome in patients with dermatomyositis. J Rheumatol 35:1838–1841PubMed
15.
go back to reference Coffernils M, Soupart A, Pradier O, Feremans W, Neve P, Decaux G (1992) Hyperferritinemia in adult onset Still's disease and the hemophagocytic syndrome. J Rheumatol 19:1425–1427PubMed Coffernils M, Soupart A, Pradier O, Feremans W, Neve P, Decaux G (1992) Hyperferritinemia in adult onset Still's disease and the hemophagocytic syndrome. J Rheumatol 19:1425–1427PubMed
16.
go back to reference Hot A, Toh ML, Coppere B, Perard L, Madoux MH, Mausservey C et al (2010) Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features and long-term outcome: a case-control study of 8 patients. Medicine 89:37–46PubMedCrossRef Hot A, Toh ML, Coppere B, Perard L, Madoux MH, Mausservey C et al (2010) Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features and long-term outcome: a case-control study of 8 patients. Medicine 89:37–46PubMedCrossRef
17.
go back to reference Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H et al (1992) Preliminary criteria for classification of adult Still's disease. J Rheumatol 19:424–430PubMed Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H et al (1992) Preliminary criteria for classification of adult Still's disease. J Rheumatol 19:424–430PubMed
18.
go back to reference Cush JJ, Medsger TA Jr, Christy WC, Herbert DC, Cooperstein LA (1987) Adult-onset Still's disease. Clinical course and outcome. Arthritis Rheum 30:186–194PubMedCrossRef Cush JJ, Medsger TA Jr, Christy WC, Herbert DC, Cooperstein LA (1987) Adult-onset Still's disease. Clinical course and outcome. Arthritis Rheum 30:186–194PubMedCrossRef
19.
go back to reference Zen M, Canova M, Campana C, Bettio S, Nalotto L, Rampudda M et al (2011) The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev 10:305–310PubMedCrossRef Zen M, Canova M, Campana C, Bettio S, Nalotto L, Rampudda M et al (2011) The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev 10:305–310PubMedCrossRef
20.
go back to reference Hoshino T, Ohta A, Yang D, Kawamoto M, Kikuchi M, Inoue Y et al (1998) Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease. J Rheumatol 25:396–398PubMed Hoshino T, Ohta A, Yang D, Kawamoto M, Kikuchi M, Inoue Y et al (1998) Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease. J Rheumatol 25:396–398PubMed
21.
go back to reference Fujii T, Nojima T, Yasuoka H, Satoh S, Nakamura K, Kuwana M et al (2001) Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology 40:1398–1404PubMedCrossRef Fujii T, Nojima T, Yasuoka H, Satoh S, Nakamura K, Kuwana M et al (2001) Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology 40:1398–1404PubMedCrossRef
22.
go back to reference Chen DY, Lan JL, Lin FJ, Hsieh TY (2004) Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol 31:2189–2198PubMed Chen DY, Lan JL, Lin FJ, Hsieh TY (2004) Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol 31:2189–2198PubMed
23.
go back to reference Ruth JH, Volin MV, Haines GK 3rd, Woodruff DC, Katschke KJ Jr, Woods JM et al (2001) Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum 44:1568–1581PubMedCrossRef Ruth JH, Volin MV, Haines GK 3rd, Woodruff DC, Katschke KJ Jr, Woods JM et al (2001) Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum 44:1568–1581PubMedCrossRef
24.
go back to reference Matsunawa M, Isozaki T, Odai T, Yajima N, Takeuchi HT, Negishi M et al (2006) Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis. Arthritis Rheum 54:3408–3416PubMedCrossRef Matsunawa M, Isozaki T, Odai T, Yajima N, Takeuchi HT, Negishi M et al (2006) Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis. Arthritis Rheum 54:3408–3416PubMedCrossRef
25.
go back to reference Matsunawa M, Odai T, Wakabayashi K, Isozaki T, Yajima N, Miwa Y et al (2009) Elevated serum levels of soluble CX3CL1 in patients with microscopic polyangiitis. Clin Exp Rheumatol 27:72–78PubMed Matsunawa M, Odai T, Wakabayashi K, Isozaki T, Yajima N, Miwa Y et al (2009) Elevated serum levels of soluble CX3CL1 in patients with microscopic polyangiitis. Clin Exp Rheumatol 27:72–78PubMed
26.
go back to reference Kasama T, Wakabayashi K, Sato M, Takahashi R, Isozaki T (2010) Relevance of the CX3CL1/fractalkine-CX3CR1 pathway in vasculitis and vasculopathy. Transl Res 155:20–26PubMedCrossRef Kasama T, Wakabayashi K, Sato M, Takahashi R, Isozaki T (2010) Relevance of the CX3CL1/fractalkine-CX3CR1 pathway in vasculitis and vasculopathy. Transl Res 155:20–26PubMedCrossRef
27.
go back to reference Suzuki F, Nanki T, Imai T, Kikuchi H, Hirohata S, Kohsaka H et al (2005) Inhibition of CX3CL1 (fractalkine) improves experimental autoimmune myositis in SJL/J mice. J Immunol 175:6987–6996PubMed Suzuki F, Nanki T, Imai T, Kikuchi H, Hirohata S, Kohsaka H et al (2005) Inhibition of CX3CL1 (fractalkine) improves experimental autoimmune myositis in SJL/J mice. J Immunol 175:6987–6996PubMed
28.
go back to reference Murphy G, Caplice N, Molloy M (2008) Fractalkine in rheumatoid arthritis: a review to date. Rheumatology 47:1446–1451PubMedCrossRef Murphy G, Caplice N, Molloy M (2008) Fractalkine in rheumatoid arthritis: a review to date. Rheumatology 47:1446–1451PubMedCrossRef
29.
go back to reference Lambotte O, Cacoub P, Costedoat N, Le Moel G, Amoura Z, Piette JC (2003) High ferritin and low glycosylated ferritin may also be a marker of excessive macrophage activation. J Rheumatol 30:1027–1028PubMed Lambotte O, Cacoub P, Costedoat N, Le Moel G, Amoura Z, Piette JC (2003) High ferritin and low glycosylated ferritin may also be a marker of excessive macrophage activation. J Rheumatol 30:1027–1028PubMed
30.
go back to reference Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 19:423–474PubMedCrossRef Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 19:423–474PubMedCrossRef
31.
go back to reference Kobayashi K, Kaneda K, Kasama T (2001) Immunopathogenesis of delayed-type hypersensitivity. Microsc Res Tech 53:241–245PubMedCrossRef Kobayashi K, Kaneda K, Kasama T (2001) Immunopathogenesis of delayed-type hypersensitivity. Microsc Res Tech 53:241–245PubMedCrossRef
32.
go back to reference Chen DY, Lan JL, Lin FJ, Hsieh TY, Wen MC (2004) Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease. Ann Rheum Dis 63:1300–1306PubMedCrossRef Chen DY, Lan JL, Lin FJ, Hsieh TY, Wen MC (2004) Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease. Ann Rheum Dis 63:1300–1306PubMedCrossRef
33.
go back to reference Hildesheim A, Schiffman MH, Tsukui T, Swanson CA, Lucci J 3rd, Scott DR et al (1997) Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease. Cancer Epidemiol Biomarkers Prev 6:807–813PubMed Hildesheim A, Schiffman MH, Tsukui T, Swanson CA, Lucci J 3rd, Scott DR et al (1997) Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease. Cancer Epidemiol Biomarkers Prev 6:807–813PubMed
34.
go back to reference Fraticelli P, Sironi M, Bianchi G, D'Ambrosio D, Albanesi C, Stoppacciaro A et al (2001) Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 107:1173–1181PubMedCrossRef Fraticelli P, Sironi M, Bianchi G, D'Ambrosio D, Albanesi C, Stoppacciaro A et al (2001) Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 107:1173–1181PubMedCrossRef
35.
go back to reference Nakahara H, Mima T, Yoshio-Hoshino N, Matsushita M, Hashimoto J, Nishimoto N (2009) A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years. Mod Rheumatol 19:69–72PubMedCrossRef Nakahara H, Mima T, Yoshio-Hoshino N, Matsushita M, Hashimoto J, Nishimoto N (2009) A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years. Mod Rheumatol 19:69–72PubMedCrossRef
36.
go back to reference De Bandt M, Saint-Marcoux B (2009) Tocilizumab for multirefractory adult-onset Still's disease. Ann Rheum Dis 68:153–154PubMedCrossRef De Bandt M, Saint-Marcoux B (2009) Tocilizumab for multirefractory adult-onset Still's disease. Ann Rheum Dis 68:153–154PubMedCrossRef
37.
go back to reference Perdan-Pirkmajer K, Praprotnik S, Tomsic M (2010) A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature. Clin Rheumatol 29:1465–1467PubMedCrossRef Perdan-Pirkmajer K, Praprotnik S, Tomsic M (2010) A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature. Clin Rheumatol 29:1465–1467PubMedCrossRef
38.
go back to reference Ancuta P, Moses A, Gabuzda D (2004) Transendothelial migration of CD16+ monocytes in response to fractalkine under constitutive and inflammatory conditions. Immunobiology 209:11–20PubMedCrossRef Ancuta P, Moses A, Gabuzda D (2004) Transendothelial migration of CD16+ monocytes in response to fractalkine under constitutive and inflammatory conditions. Immunobiology 209:11–20PubMedCrossRef
39.
go back to reference Efthimiou P, Georgy S (2006) Pathogenesis and management of adult-onset Still's disease. Semin Arthritis Rheum 36:144–152PubMedCrossRef Efthimiou P, Georgy S (2006) Pathogenesis and management of adult-onset Still's disease. Semin Arthritis Rheum 36:144–152PubMedCrossRef
40.
go back to reference Emmenegger U, Reimers A, Frey U, Fux C, Bihl F, Semela D et al (2002) Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation. Swiss Med Wkly 132:230–236PubMed Emmenegger U, Reimers A, Frey U, Fux C, Bihl F, Semela D et al (2002) Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation. Swiss Med Wkly 132:230–236PubMed
Metadata
Title
Correlation of serum CX3CL1 level with disease activity in adult-onset Still's disease and significant involvement in hemophagocytic syndrome
Authors
Tsuyoshi Kasama
Hidekazu Furuya
Ryo Yanai
Kumiko Ohtsuka
Ryo Takahashi
Nobuyuki Yajima
Yusuke Miwa
Kazuo Kobayashi
Publication date
01-05-2012
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 5/2012
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-012-1952-1

Other articles of this Issue 5/2012

Clinical Rheumatology 5/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.